Eryaspase given fast track designation in US for second-line use in pancreatic cancer

Eryaspase (erythrpcyte encapsulated asparaginase), is currently being evaluated in a Phase 3 trial (TRYbeCA-1) in second-line metastatic pancreatic cancer. with results expected in the second half of 2021.

Biospace Inc.